Moleculin Biotech (MBRX) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Moleculin Biotech (MBRX) is Moderate Underperform.

The composite score behind that read is -0.36, weighing +0.00 of bullish evidence against -0.52 bearish.

Moleculin Biotech last closed at $0.44, +4.76% on the session.

Against the IVW growth benchmark the position is +3.96% over the forecast window.

The read is built from 15 underlying insights — 0 bullish and 15 bearish.

Agreement across those insights is 100%.

20 graded predictions for MBRX so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Moleculin Biotech in the 1st percentile on return on equity, where 100 is best.

Moleculin Biotech is classified under Health Care / Biotechnology, with a market capitalisation of $8.64M.

StockMap tracks Moleculin Biotech as the 359th largest of the 381 companies it covers in the Biotechnology industry, part of the Health Care sector.

Across that group the current two-week reads are 301 Neutral, 63 Moderate Underperform and 17 Moderate Outperform.

On that composite Moleculin Biotech ranks 376th of 381 in the group, against a group median of -0.08.